Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Bajaj Healthcare Ltd

₹ 4101.43%
07 Jan 4:01 p.m. – close price
🔗bajajhealth.com•BSE: 539872•NSE: BAJAJHCARE
Market Cap₹ 1,298 Cr.
Current Price₹ 410
High / Low₹ 745
Stock P/E25.4
Book Value₹ 154
Dividend Yield0.24 %
ROCE11.4 %
ROE10.7 %
Face Value₹ 5.00
Sales₹ 574 Cr.
OPM14.8 %
Mar Cap₹ 1,298 Cr.

ABOUT

Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]

KEY POINTS

Business Overview:[1][2][3]BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+clients, exporting bulk drugs to ~62+countries in Europe, USA, Africa, Australia, etc.

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceCapacity Expansion And ProductsPreferential IssuanceOrder Book PositionJv Partnerships AcquisitionsRevenue Guidance Vs ActualsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1782.6037.05427717.600.903124.952.5614478.318.9320.2154964.0130.1211543.963117.955.5012.970.07
2.Divi's Lab.6642.5070.94176292.380.45689.0035.102715.0016.1220.4410029.0032.372485.00689.0011.4413.530.01
3.Torrent Pharma.4091.2563.92138464.730.78591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.3913.260.33
4.Cipla1467.9021.80118607.610.891353.373.737589.447.6422.7228349.5725.405441.141351.173.6014.720.01
5.Dr Reddy's Labs1242.8017.97103748.510.641336.807.288828.309.8322.6934310.0024.645772.201347.102.8812.950.16
6.Lupin2214.3023.36101043.200.541484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1512.410.32
7.Mankind Pharma2305.0054.3995107.000.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.228.890.55
8.Bajaj Healthcare410.2025.371298.260.2411.1149.28147.9111.1411.44574.0114.7951.1812.452.664.980.49
–Median: 150 Co.410.0530.811757.370.1113.0312.32157.210.8414.98582.8715.9644.5513.733.158.60.22

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
133109123130132149154134154195101133148
Expenses
1028910110810812413211814316182109121
Operating Profit
30202222242522161234192527
Other Income
-6-7-1-55-01-7-3613-5-740
Profit before tax
15-18-489145-331122-31415
Tax %
26%58%-39%-0%23%17%21%-10%1%26%4%30%24%
Net Profit
11-212-487124-301116-3911
EPS in Rs
4.00-0.803.71-17.472.583.751.30-10.843.545.93-1.253.003.52

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
205218223231327370410657680646473543574
Expenses
186189193200288327362521561534397460489
Operating Profit
19293031394348136119112768385
Other Income
000221771-19-1051613
Interest
788888781318302822
Depreciation
99911111112161817282827
Profit before tax
31214142324361199058-864349
Net Profit
2888151625837143-844046
EPS in Rs
2.198.343.042.835.505.919.1430.1125.8715.59-30.3612.5114.52
Dividend Payout %
0%0%0%0%5%0%0%5%6%6%-3%8%–

Compounded Profit Growth

10 Years:18%
5 Years:10%
3 Years:-18%
TTM:50%

Compounded Sales Growth

10 Years:10%
5 Years:6%
3 Years:-7%
TTM:13%

Return on Equity

10 Years:13%
5 Years:13%
3 Years:4%
Last Year:11%

Stock Price CAGR

10 Years:%
5 Years:9%
3 Years:-2%
1 Year:-31%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
22777714141414141616
Reserves
28788292107122164245315354265450471
Borrowings
72708175878191181257415333223238
Other Liabilities
4338394568577486136115154144114
Total Liabilities
145189209219268267343526721898765833839
Fixed Assets
56108130128127128162208270366253238251
Gross Block
100.48161.52191.39199.88209.65222.23267.83329.25401.73525.01422.98436.47–
Accumulated Depreciation
44.6053.0261.8371.9583.0393.74105.59121.13131.98159.32170.23198.02–
CWIP
3110215575222736
Investments
0000005000000
Other Assets
87797891140137170260399510506591582
Total Assets
145189209219268267343526721898765833839

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
17282522172521441-229222
Cash from Investing Activity
-9-17-31-8-12-13-28-109-75-93-11-15
Cash from Financing Activity
-8-115-132-1337562131-97-6
Net Cash Flow
1-0-007-0-410-1216-160

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
988670839077885599110139169
Inventory Days
5150564557455494143199206206
Days Payable
68634651744580679481128122
Cash Conversion Cycle
8173807873776282148228217254
Working Capital Days
-25-11-17-401224344027-0140
ROCE %
10%16%13%13%16%16%18%36%20%14%8%11%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
67.42%67.49%67.49%67.69%67.73%67.74%67.74%59.19%59.19%59.19%59.19%59.19%
FIIs
0.94%0.78%0.69%0.66%0.74%0.53%0.00%1.07%1.01%1.05%1.09%1.12%
DIIs
0.34%0.34%0.34%0.43%0.48%0.43%0.00%1.97%2.36%2.52%3.16%2.99%
Public
31.30%31.38%31.48%31.22%31.06%31.31%32.27%37.77%37.45%37.25%36.56%36.70%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Bajaj Healthcare Receives SEBI Compliance Certificate for Q4 FY26 Dematerialization

7th April 2026, 6:44 pm

Bajaj Healthcare: Promoter Anil Champalal Jain Converts Warrants, Stake Update

21st March 2026, 12:37 am

Promoter Group Acquires 7,095 Shares in Bajaj Healthcare

19th March 2026, 4:31 pm

Bajaj Healthcare Allots Over 2 Crore Shares on Warrant Conversion, Raises ₹527 Cr

19th March 2026, 12:14 am

Promoter Group Member Acquires Additional Shares in Bajaj Healthcare

17th March 2026, 10:48 pm

Published by Other Websites

External media mentions & references

Nifty 50 Crumbles Below 23,000; 700 Stocks Plunge to 52-Week Lows

16th March 2026, 1:02 pm

Bajaj Healthcare Surges 7% on Stellar Q3 Profit Growth, Revenue Jumps 31%

19th January 2026, 10:48 am

RIL, Banks Post Q3 Results; Tech Stocks Show Mixed Fortunes

19th January 2026, 7:09 am

Bajaj Healthcare Profit Jumps 34% on Strong Revenue, Margin Gains

16th January 2026, 7:28 pm

Stocks to Watch Jan 16: Infosys Profit Dips, ICICI Pru AMC Surges as Earnings Season Unfolds

16th January 2026, 8:06 am

News Articles

Editorial & research coverage

Bajaj Healthcare Surges 7% on Stellar Q3 Profit Growth, Revenue Jumps 31%
Bajaj Healthcare Surges 7% on Stellar Q3 Profit Growth, Revenue Jumps 31%

19th January 2026, 10:48 am

RIL, Banks Post Q3 Results; Tech Stocks Show Mixed Fortunes
RIL, Banks Post Q3 Results; Tech Stocks Show Mixed Fortunes

19th January 2026, 7:09 am

Bajaj Healthcare Profit Jumps 34% on Strong Revenue, Margin Gains
Bajaj Healthcare Profit Jumps 34% on Strong Revenue, Margin Gains

16th January 2026, 7:28 pm

India's 'Woman Warren Buffett' Unveils 2 Stocks Trading at Huge Discounts – Opportunity or Trap?
India's 'Woman Warren Buffett' Unveils 2 Stocks Trading at Huge Discounts – Opportunity or Trap?

29th November 2025, 7:06 am

Documents

Announcements

Announcement under Regulation 30 (LODR)-Change in Management

2d - Appointed Purnima Dhanraj Amin as independent director, Jan 05, 2026–Jan 04, 2031, subject to shareholders' approval.

Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015

31 Dec - CDSCO approved on Dec 31, 2025 to conduct clinical trial and bioequivalence study of Suvorexant tablets.

Closure of Trading Window
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Announcement under Regulation 30 (LODR)-Investor Presentation

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Credit Ratings

Rating update

15 May 2025 from fitch

Rating update

28 Feb 2024 from crisil

Rating update

28 Aug 2023 from crisil

Rating update

7 Jul 2023 from crisil

Rating update

18 Nov 2022 from fitch

Rating update

6 Sep 2022 from crisil

Concalls

Dec 2025

PPT

Oct 2025

PPT

Jul 2025

PPT

Jun 2022

PPT

Aug 2020

PPT

Stock Analysis

Corporate Announcements

7th Apr 26
Impact Rating: 5
Bajaj Healthcare Limited has been issued a compliance certificate by MUFG Intime India Private Limited, confirming adherence to SEBI's Depository and Participants Regulations for the quarter ending March 31, 2026.
20th Mar 26
Impact Rating: 9
Promoter Anil Champalal Jain has disclosed the conversion of 4,55,074 convertible warrants into equity shares of Bajaj Healthcare on March 18, 2026.
19th Mar 26
Impact Rating: 8
Anil Champalal Jain, part of the promoter group, acquired 7,095 shares in Bajaj Healthcare on 17 March 2026 via open market. The promoter group's total stake is now 4.69%.
18th Mar 26
Impact Rating: 9
Bajaj Healthcare's Board approved allotting 20,79,409 equity shares via warrant conversion, raising ₹52,71,30,181.50 (₹527.13 crore) at ₹338 per share. This increases share capital to ₹16.83 crore.
17th Mar 26
Impact Rating: 7
Anil Champalal Jain, a member of Bajaj Healthcare's promoter group, has acquired 7,600 equity shares. This transaction increases the promoter group's total holding to 14,74,375 shares, representing 4.67% of the total voting capital.